The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations

Low-density lipoprotein receptor-related protein 5 (LRP5), a Wnt coreceptor, plays an important role in bone metabolism as loss-of-function and gain-of-function mutations in LRP5 result in the autosomal recessive osteoporosis-pseudoglioma syndrome and amosomal dominant high-bone mass (HBM) phenotypes, respectively. Prior studies suggested that the presence of HBM-associated LRP5 mutations results in decreased antagonism of LRP5mediated Wnt signaling. In the present study, we investigated six different HBM-LRP5 mutations and confirm that neither Dickkopfl (DKKI) nor sclerostin efficiently inhibits HBM-LRP5 signaling. In addition, when coexpressed, DKKI and sclerostin do not inhibit HBM-LRP5 mutants better than either inhibitor by itself. Also, DKKI and sclerostin do not simultaneously bind to wild-type LRP5, and DKKI is able to displace sclerostin from previously formed sclerostin-LRP5 complexes. In conclusion, our results indicate that DKK1 and sclerostin are independent, and not synergistic, regulators of LRP5 signaling and that the function of each is impaired by HBM-LRP5 mutations.